You can buy or sell ContraFect and other stocks, options, ETFs, and crypto commission-free!
ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. Read More The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Yonkers, New York
52 Week High
52 Week Low
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease Presentations to include new data from the Phase 2 superiority design trial of exebacase for the treatment of Staph aureus bacteremia, including endocarditis YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistan...
Yahoo FinanceApr 30
CFRX: Additional Phase 2 Data Presented at ECCMID…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Additional Data Presented for Exebacase Phase 2 Trial On April 16, 2019, Contrafect Corp. (CFRX) announced the presentation of new data from the Phase 2 clinical trial of exebacase (CF-301) for the treatment of Staphylococcus aureus bacteremia including endocarditis at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data was presented by Vance G. Fowler, Jr., M.D., Prof...
-$0.10 per share
-$0.08 per share